548P Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study
Anna V. Tinker(University of British Columbia), Bhavana Pothuri(Gynecologic Oncology Group), L. Gilbert(McGill University Health Centre), Renaud Sabatier(Aix-Marseille Université), J. Brown(Levine Cancer Institute), Sharad Ghamande(Augusta University Health), Cara Mathews(Providence College), David M. O’Malley(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Valentina Boni(Hospital Universitario Quirónsalud Madrid), Adriano Gravina(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Susana Banerjee(Royal Marsden NHS Foundation Trust), Rowan Miller(St Bartholomew's Hospital), J. Pikiel, Mansoor Raza Mirza(Copenhagen University Hospital), Tao Duan(GlaxoSmithKline (United States)), G. Antony(GlaxoSmithKline (United Kingdom)), S. Zildjian(GlaxoSmithKline (United States)), Eleftherios Zografos(GlaxoSmithKline (United Kingdom)), Jennifer Veneris(GlaxoSmithKline (United States)), Ana Oaknin(Vall d'Hebron Hospital Universitari)
Cited by 2
Abstract
Related Papers
No related papers found
Powered by citation graph analysis